Blue-light filtering IOLs

Article

Making driving safer in glare conditions

When driving in high-glare conditions the visibilities of objects are reduced, and lowcontrast objects may be rendered invisible. A major cause of the problems associated with glare is that light is scattered within the eye onto the retina (veiling glare) thus reducing the contrast of the retinal image. This reduction of contrast is called disability glare.

Study design

The main indicator of driving safety that was used was the safety margin at the point when the driver initiated the turn. This safety margin can be thought of as the amount of time that would be leftover if the driver made the turn: a safety margin of +2 seconds means that the driver could finish their turn and leave the intersection 2 seconds before the oncoming car entered the same intersection (a safe situation) while a safety margin of 0 seconds means the back bumper of the driver's car would clear the intersection at the exact instant the oncoming vehicles' front bumper entered the intersection (a very unsafe situation). A smaller safety margin in this context increases the likelihood of a collision with the oncoming vehicle. Of particular interest was whether the safety margin used by drivers for turns changed in the presence of glare and whether this change was effected by the used of blue-light filtering IOLs.

Across the two studies a total of 67 patients (mean age of 72 years) previously implanted with IOLs developed by Alcon Laboratories were evaluated. There were two blue light-filtering groups: 17 patients implanted with blue-light filtering, acrylic IOLs (AcrySof Model SA60AT) and 18 patients implanted with blue-light filtering, toric IOLs (AcrySof Models SN6ATT or SN60TT). The control groups (a total of 32 patients) were implanted with IOLs without UVonly filtering (AcrySof Model SA60AT).

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.